Themed "Global IVD Innovation & Cross-Regional Integration," this groundbreaking event brings together distinguished experts from around the world to explore the future of diagnostics.

CareDx said on Wednesday that it has priced a planned $125 million public stock offering at $32 per share. The Brisbane, California-based molecular diagnostics firm said it will offer 3,906,250 shares of its common stock through the transac

Researchers at Johns Hopkins University have developed a gene editing approach they call very fast CRISPR (vfCRISPR) that is capable of creating double-strand breaks (DSBs) in seconds, and at the submicrometer scale. During gene editing, it

Roche subsidiary Foundation Medicine announced Friday it has acquired precision oncology firm Lexent Bio to help expand its liquid biopsy platforms and advance cancer care. Financial and other details of the deal were not disclosed. Lexent

A recent genetic association study of people who are naturally thin has tied variants in the anaplastic lymphoma kinase (ALK) gene to thinness.

Genedrive said Friday that it has received the CE mark for its Genedrive 96 SARS-CoV-2 Kit and is making it available for sale in the European Union, including the UK, and other countries that accept the mark.

P23 Labs has received Emergency Use Authorization for its coronavirus PCR test from the US Food and Drug Administration.

The US Food and Drug Administration on Thursday granted separate Emergency Use Authorizations (EUAs) for PCR-based SARS-CoV-2 tests developed by South Korean diagnostic test makers BioCore, SolGent, and Seasun Biomaterials.

Agilent Technologies reported after the close of the market on Thursday that its second quarter 2020 revenue growth was flat year over year. The firm noted that core revenues, which excludes the impact of currency and acquisitions and divest

The US Food and Drug Administration on Wednesday announced the approval of AstraZeneca and Merck's olaparib (Lynparza) for metastatic castration-resistant prostate cancer patients with homologous recombination repair deficiency.

Proteomics firm Nautilus Biotechnology announced Thursday it has closed an oversubscribed $76 million Series B financing round.